Recruiting
Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer
This study assesses breast cancer screening adherence for women at moderately increased risk for developing breast cancer based on gene mutation status or empiric risk model estimates. It also seeks to determine facilitators and barriers to screening.
ClinicalTrials.gov IDNCT07076147
PhaseNot Applicable
Enrollment150
SponsorUniversity of Southern California
Age30 Years – 75 Years
SexFEMALE
Conditions studied
Breast Carcinoma
About this study
This study assesses breast cancer screening adherence for women at moderately increased risk for developing breast cancer based on gene mutation status or empiric risk model estimates. It also seeks to determine facilitators and barriers to screening.
Interventions
- Other: Non-Interventional Study — Non-interventional study
Primary outcomes
- Proportion of women who undergo a screening breast MRI within 12 months of genetic test counseling (Up to 2 years)
Eligibility information
Inclusion Criteria:
* \* \>= 30 years
* =\< 75 years
* Women with either:
* Genetic test results showing moderately increased breast cancer risk due to a pathogenic/likely pathogenic variant in ATM, CHEK2, BARD1, RAD51C, or RAD51D (Mutation carrier group) OR
* Calculated lifetime breast cancer risk estimates between 20% and 40% according to the Tyrer-Cuzick V8.0B empiric risk model (Empiric risk group)
* Patients provided breast cancer risk assessments by genetic counselors at USC Norris or LA General Hospital beginning in 2021 and at least 12 months ago
* Women recommended to undergo annual breast MRI and/or annual mammogram beginning at the time of their genetic counseling risk assessment
* English or Spanish speaking patients
Exclusion Criteria:
* \* History of breast cancer before genetic counseling at University of Southern California (USC)
* Any metastatic cancer diagnosis at time of genetic counseling risk assessment
* Deceased
* Patient underwent a risk reducing mastectomy before their genetic counseling risk assessment
Study locations
- Los Angeles General Medical Center, Los Angeles, California 90033 United States
- USC / Norris Comprehensive Cancer Center, Los Angeles, California 90033 United States
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-15.